LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Home・Akciju saraksts・Talphera Inc.

Talphera Inc.

Slēgts

1.07 -2.73

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.03

Max

1.13

Galvenie mērījumi
By Trading Economics
Darbinieki	13

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+192.79% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-15M 46M
Iepriekšējā atvēršanas cena	3.8
Iepriekšējā slēgšanas cena	1.07

Talphera Inc. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 19. dec. 17:29 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

2025. g. 19. dec. 16:47 UTC

Galvenie tirgus virzītāji

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

2025. g. 19. dec. 16:10 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

2025. g. 19. dec. 22:33 UTC

Peļņas

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

2025. g. 19. dec. 22:19 UTC

Peļņas

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025. g. 19. dec. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 21:44 UTC

Peļņas

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025. g. 19. dec. 21:38 UTC

Peļņas

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

2025. g. 19. dec. 21:00 UTC

Tirgus saruna

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

2025. g. 19. dec. 20:23 UTC

Tirgus saruna

Oil Futures End Down Week on Up Note -- Market Talk

2025. g. 19. dec. 20:14 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

2025. g. 19. dec. 18:38 UTC

Tirgus saruna

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

2025. g. 19. dec. 18:00 UTC

Tirgus saruna

Peļņas

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

2025. g. 19. dec. 17:41 UTC

Peļņas

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025. g. 19. dec. 17:24 UTC

Tirgus saruna

Peļņas

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

2025. g. 19. dec. 17:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 19. dec. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 19. dec. 16:29 UTC

Peļņas

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

2025. g. 19. dec. 16:20 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

2025. g. 19. dec. 16:19 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

2025. g. 19. dec. 16:18 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

2025. g. 19. dec. 16:16 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 19. dec. 16:16 UTC

Tirgus saruna

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

2025. g. 19. dec. 16:05 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 16:04 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 15:37 UTC

Tirgus saruna

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

2025. g. 19. dec. 15:21 UTC

Tirgus saruna

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

2025. g. 19. dec. 15:09 UTC

Tirgus saruna

Gold Flat But Set for Weekly Gains -- Market Talk

2025. g. 19. dec. 15:09 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 19. dec. 15:09 UTC

Peļņas

FedEx Earnings Were Strong. The Stock Is Down. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Talphera Inc. Prognoze

Cenas mērķis

By TipRanks

192.79% augšup

Prognoze 12 mēnešiem

Vidējais 3.25 USD 192.79%

Augstākais 3.5 USD

Zemākais 3 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Talphera Inc. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Talphera Inc. — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Par Talphera Inc.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.